Ironwood Pharmaceuticals Inc. Class A Common Stock
IRWDUnited States
5 filed reports · 227 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 689 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 581 | Dec 2025 |
Financial data
227 concepts · 1,270 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial225 concepts · 1,259 facts · Mar 2024 to Jun 2026
- Comprehensive income net of tax12 · Mar 2024 to Jun 2026
- Costs and expenses12 · Mar 2024 to Jun 2026
- Earnings per share basic12 · Mar 2024 to Jun 2026
- Earnings per share diluted12 · Mar 2024 to Jun 2026
- Net income loss12 · Mar 2024 to Jun 2026
- Nonoperating income expense12 · Mar 2024 to Jun 2026
- Profit loss12 · Mar 2024 to Jun 2026
- Revenue12 · Mar 2024 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest12 · Mar 2024 to Jun 2026
- Allocated share based compensation expense11 · Jun 2024 to Jun 2026
- Allocated share based compensation expense net of tax11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
- Employee service share based compensation tax benefit from compensation expense11 · Jun 2024 to Jun 2026
- Income tax expense benefit11 · Jun 2024 to Jun 2026
- Interest expense nonoperating11 · Jun 2024 to Jun 2026
- Investment income net11 · Jun 2024 to Jun 2026
- Lease cost11 · Jun 2024 to Jun 2026
- Net income loss available to common stockholders basic11 · Jun 2024 to Jun 2026
- Net income loss available to common stockholders diluted11 · Jun 2024 to Jun 2026
- Number of reportable segments11 · Jun 2024 to Jun 2026
- Operating income loss11 · Jun 2024 to Jun 2026
- Operating lease cost11 · Jun 2024 to Jun 2026
- Operating lease weighted average discount rate percent11 · Jun 2024 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent11 · Jun 2024 to Jun 2026
Product1 concepts · 9 facts · Jun 2024 to Dec 2025
- Revenue9 · Jun 2024 to Dec 2025
Geography1 concepts · 2 facts · Dec 2024 to Dec 2025
- Research and development expense2 · Dec 2024 to Dec 2025
Segments
11 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service2 members · 9 facts
- Collaborative Arrangement Other Agreements7 · Jun 2024 to Dec 2025
- Collaborative Arrangements2 · Dec 2024 to Dec 2025
Statement geographical1 member · 2 facts
- North America2 · Dec 2024 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Feb 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2026 Q1May 7, 2026
- FY2025 Q4Feb 25, 2026
- FY2024 Q4Feb 27, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.